Skip to Content

Cimduo Approval History

FDA Approved: Yes (First approved February 28, 2018)
Brand name: Cimduo
Generic name: lamivudine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Mylan Pharmaceuticals Inc.
Treatment for: HIV Infection

Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Development History and FDA Approval Process for Cimduo

DateArticle
Mar  2, 2018Approval Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide